Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
25
ONC Quote, Financials, Valuation and Earnings
Last price:
$296.00
Seasonality move
:
-2.62%
Day range:
$293.70 - $300.60
52-week range:
$196.45 - $385.22
Dividend yield:
0%
P/E ratio:
118.52x
P/S ratio:
6.33x
P/B ratio:
8.25x
Volume:
355.8K
Avg. volume:
273.2K
1-year change:
16.21%
Market cap:
$33.1B
Revenue:
$5.4B
EPS (TTM):
$2.52
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ONC
BeOne Medicines Ltd.
|
$1.5B | $1.30 | 27.83% | 6689.47% | $409.68 |
|
ACIU
AC Immune SA
|
$878.5K | -$0.13 | 11.32% | -18.31% | $9.20 |
|
BPMUF
Basilea Pharmaceutica AG
|
$93.1M | -- | -- | -- | -- |
|
CSBTF
Kuros Biosciences Ltd.
|
-- | -- | -- | -- | -- |
|
ELVAF
EvoNext Holdings SA
|
-- | -- | -- | -- | -- |
|
SPHDF
Santhera Pharmaceuticals Holding AG
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ONC
BeOne Medicines Ltd.
|
$299.02 | $409.68 | $33.1B | 118.52x | $0.00 | 0% | 6.33x |
|
ACIU
AC Immune SA
|
$2.84 | $9.20 | $285.7M | -- | $0.00 | 0% | 55.40x |
|
BPMUF
Basilea Pharmaceutica AG
|
$71.00 | -- | $871.3M | 19.33x | $0.00 | 0% | 3.46x |
|
CSBTF
Kuros Biosciences Ltd.
|
$32.00 | -- | $1.3B | -- | $0.00 | 0% | 9.78x |
|
ELVAF
EvoNext Holdings SA
|
$1.1700 | -- | $8.4M | 5.90x | $0.00 | 0% | 0.61x |
|
SPHDF
Santhera Pharmaceuticals Holding AG
|
$21.15 | -- | $274.4M | 1.45x | $0.00 | 0% | 4.78x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ONC
BeOne Medicines Ltd.
|
31.44% | 0.327 | 5.95% | 2.98x |
|
ACIU
AC Immune SA
|
6.95% | 3.782 | 2.01% | 1.10x |
|
BPMUF
Basilea Pharmaceutica AG
|
85.07% | 0.818 | -- | 2.96x |
|
CSBTF
Kuros Biosciences Ltd.
|
-- | -0.557 | -- | 1.61x |
|
ELVAF
EvoNext Holdings SA
|
-- | 0.078 | -- | -- |
|
SPHDF
Santhera Pharmaceuticals Holding AG
|
33% | -7.351 | -- | 0.51x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ONC
BeOne Medicines Ltd.
|
$1.3B | $185.8M | 5.51% | 7.54% | 12.35% | $381.2M |
|
ACIU
AC Immune SA
|
-- | -$19.6M | -72.31% | -75.88% | -1671.93% | -$24.4M |
|
BPMUF
Basilea Pharmaceutica AG
|
-- | -- | -0.84% | -15.42% | -- | -- |
|
CSBTF
Kuros Biosciences Ltd.
|
-- | -- | -6.35% | -6.35% | -- | -- |
|
ELVAF
EvoNext Holdings SA
|
-- | -- | -- | -- | -- | -- |
|
SPHDF
Santhera Pharmaceuticals Holding AG
|
-- | -- | 123.12% | 276.68% | -- | -- |
BeOne Medicines Ltd. vs. Competitors
-
Which has Higher Returns ONC or ACIU?
AC Immune SA has a net margin of 4.44% compared to BeOne Medicines Ltd.'s net margin of -1688.87%. BeOne Medicines Ltd.'s return on equity of 7.54% beat AC Immune SA's return on equity of -75.88%.
Company Gross Margin Earnings Per Share Invested Capital ONCBeOne Medicines Ltd.88.43% $0.58 $6.4B ACIUAC Immune SA-- -$0.20 $84.3M -
What do Analysts Say About ONC or ACIU?
BeOne Medicines Ltd. has a consensus price target of $409.68, signalling upside risk potential of 37.03%. On the other hand AC Immune SA has an analysts' consensus of $9.20 which suggests that it could grow by 223.77%. Given that AC Immune SA has higher upside potential than BeOne Medicines Ltd., analysts believe AC Immune SA is more attractive than BeOne Medicines Ltd..
Company Buy Ratings Hold Ratings Sell Ratings ONCBeOne Medicines Ltd.17 0 1 ACIUAC Immune SA4 0 0 -
Is ONC or ACIU More Risky?
BeOne Medicines Ltd. has a beta of 0.532, which suggesting that the stock is 46.826% less volatile than S&P 500. In comparison AC Immune SA has a beta of 1.637, suggesting its more volatile than the S&P 500 by 63.73%.
-
Which is a Better Dividend Stock ONC or ACIU?
BeOne Medicines Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AC Immune SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BeOne Medicines Ltd. pays -- of its earnings as a dividend. AC Immune SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ONC or ACIU?
BeOne Medicines Ltd. quarterly revenues are $1.5B, which are larger than AC Immune SA quarterly revenues of $1.2M. BeOne Medicines Ltd.'s net income of $66.8M is higher than AC Immune SA's net income of -$19.8M. Notably, BeOne Medicines Ltd.'s price-to-earnings ratio is 118.52x while AC Immune SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BeOne Medicines Ltd. is 6.33x versus 55.40x for AC Immune SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ONCBeOne Medicines Ltd.6.33x 118.52x $1.5B $66.8M ACIUAC Immune SA55.40x -- $1.2M -$19.8M
-
Which has Higher Returns ONC or BPMUF?
Basilea Pharmaceutica AG has a net margin of 4.44% compared to BeOne Medicines Ltd.'s net margin of --. BeOne Medicines Ltd.'s return on equity of 7.54% beat Basilea Pharmaceutica AG's return on equity of -15.42%.
Company Gross Margin Earnings Per Share Invested Capital ONCBeOne Medicines Ltd.88.43% $0.58 $6.4B BPMUFBasilea Pharmaceutica AG-- -- $125.1M -
What do Analysts Say About ONC or BPMUF?
BeOne Medicines Ltd. has a consensus price target of $409.68, signalling upside risk potential of 37.03%. On the other hand Basilea Pharmaceutica AG has an analysts' consensus of -- which suggests that it could fall by --. Given that BeOne Medicines Ltd. has higher upside potential than Basilea Pharmaceutica AG, analysts believe BeOne Medicines Ltd. is more attractive than Basilea Pharmaceutica AG.
Company Buy Ratings Hold Ratings Sell Ratings ONCBeOne Medicines Ltd.17 0 1 BPMUFBasilea Pharmaceutica AG0 0 0 -
Is ONC or BPMUF More Risky?
BeOne Medicines Ltd. has a beta of 0.532, which suggesting that the stock is 46.826% less volatile than S&P 500. In comparison Basilea Pharmaceutica AG has a beta of 0.327, suggesting its less volatile than the S&P 500 by 67.337%.
-
Which is a Better Dividend Stock ONC or BPMUF?
BeOne Medicines Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Basilea Pharmaceutica AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BeOne Medicines Ltd. pays -- of its earnings as a dividend. Basilea Pharmaceutica AG pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ONC or BPMUF?
BeOne Medicines Ltd. quarterly revenues are $1.5B, which are larger than Basilea Pharmaceutica AG quarterly revenues of --. BeOne Medicines Ltd.'s net income of $66.8M is higher than Basilea Pharmaceutica AG's net income of --. Notably, BeOne Medicines Ltd.'s price-to-earnings ratio is 118.52x while Basilea Pharmaceutica AG's PE ratio is 19.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BeOne Medicines Ltd. is 6.33x versus 3.46x for Basilea Pharmaceutica AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ONCBeOne Medicines Ltd.6.33x 118.52x $1.5B $66.8M BPMUFBasilea Pharmaceutica AG3.46x 19.33x -- --
-
Which has Higher Returns ONC or CSBTF?
Kuros Biosciences Ltd. has a net margin of 4.44% compared to BeOne Medicines Ltd.'s net margin of --. BeOne Medicines Ltd.'s return on equity of 7.54% beat Kuros Biosciences Ltd.'s return on equity of -6.35%.
Company Gross Margin Earnings Per Share Invested Capital ONCBeOne Medicines Ltd.88.43% $0.58 $6.4B CSBTFKuros Biosciences Ltd.-- -- $65M -
What do Analysts Say About ONC or CSBTF?
BeOne Medicines Ltd. has a consensus price target of $409.68, signalling upside risk potential of 37.03%. On the other hand Kuros Biosciences Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that BeOne Medicines Ltd. has higher upside potential than Kuros Biosciences Ltd., analysts believe BeOne Medicines Ltd. is more attractive than Kuros Biosciences Ltd..
Company Buy Ratings Hold Ratings Sell Ratings ONCBeOne Medicines Ltd.17 0 1 CSBTFKuros Biosciences Ltd.0 0 0 -
Is ONC or CSBTF More Risky?
BeOne Medicines Ltd. has a beta of 0.532, which suggesting that the stock is 46.826% less volatile than S&P 500. In comparison Kuros Biosciences Ltd. has a beta of 0.916, suggesting its less volatile than the S&P 500 by 8.447%.
-
Which is a Better Dividend Stock ONC or CSBTF?
BeOne Medicines Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kuros Biosciences Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BeOne Medicines Ltd. pays -- of its earnings as a dividend. Kuros Biosciences Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ONC or CSBTF?
BeOne Medicines Ltd. quarterly revenues are $1.5B, which are larger than Kuros Biosciences Ltd. quarterly revenues of --. BeOne Medicines Ltd.'s net income of $66.8M is higher than Kuros Biosciences Ltd.'s net income of --. Notably, BeOne Medicines Ltd.'s price-to-earnings ratio is 118.52x while Kuros Biosciences Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BeOne Medicines Ltd. is 6.33x versus 9.78x for Kuros Biosciences Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ONCBeOne Medicines Ltd.6.33x 118.52x $1.5B $66.8M CSBTFKuros Biosciences Ltd.9.78x -- -- --
-
Which has Higher Returns ONC or ELVAF?
EvoNext Holdings SA has a net margin of 4.44% compared to BeOne Medicines Ltd.'s net margin of --. BeOne Medicines Ltd.'s return on equity of 7.54% beat EvoNext Holdings SA's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ONCBeOne Medicines Ltd.88.43% $0.58 $6.4B ELVAFEvoNext Holdings SA-- -- -- -
What do Analysts Say About ONC or ELVAF?
BeOne Medicines Ltd. has a consensus price target of $409.68, signalling upside risk potential of 37.03%. On the other hand EvoNext Holdings SA has an analysts' consensus of -- which suggests that it could fall by --. Given that BeOne Medicines Ltd. has higher upside potential than EvoNext Holdings SA, analysts believe BeOne Medicines Ltd. is more attractive than EvoNext Holdings SA.
Company Buy Ratings Hold Ratings Sell Ratings ONCBeOne Medicines Ltd.17 0 1 ELVAFEvoNext Holdings SA0 0 0 -
Is ONC or ELVAF More Risky?
BeOne Medicines Ltd. has a beta of 0.532, which suggesting that the stock is 46.826% less volatile than S&P 500. In comparison EvoNext Holdings SA has a beta of -40.297, suggesting its less volatile than the S&P 500 by 4129.699%.
-
Which is a Better Dividend Stock ONC or ELVAF?
BeOne Medicines Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. EvoNext Holdings SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BeOne Medicines Ltd. pays -- of its earnings as a dividend. EvoNext Holdings SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ONC or ELVAF?
BeOne Medicines Ltd. quarterly revenues are $1.5B, which are larger than EvoNext Holdings SA quarterly revenues of --. BeOne Medicines Ltd.'s net income of $66.8M is higher than EvoNext Holdings SA's net income of --. Notably, BeOne Medicines Ltd.'s price-to-earnings ratio is 118.52x while EvoNext Holdings SA's PE ratio is 5.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BeOne Medicines Ltd. is 6.33x versus 0.61x for EvoNext Holdings SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ONCBeOne Medicines Ltd.6.33x 118.52x $1.5B $66.8M ELVAFEvoNext Holdings SA0.61x 5.90x -- --
-
Which has Higher Returns ONC or SPHDF?
Santhera Pharmaceuticals Holding AG has a net margin of 4.44% compared to BeOne Medicines Ltd.'s net margin of --. BeOne Medicines Ltd.'s return on equity of 7.54% beat Santhera Pharmaceuticals Holding AG's return on equity of 276.68%.
Company Gross Margin Earnings Per Share Invested Capital ONCBeOne Medicines Ltd.88.43% $0.58 $6.4B SPHDFSanthera Pharmaceuticals Holding AG-- -- $79.8M -
What do Analysts Say About ONC or SPHDF?
BeOne Medicines Ltd. has a consensus price target of $409.68, signalling upside risk potential of 37.03%. On the other hand Santhera Pharmaceuticals Holding AG has an analysts' consensus of -- which suggests that it could fall by --. Given that BeOne Medicines Ltd. has higher upside potential than Santhera Pharmaceuticals Holding AG, analysts believe BeOne Medicines Ltd. is more attractive than Santhera Pharmaceuticals Holding AG.
Company Buy Ratings Hold Ratings Sell Ratings ONCBeOne Medicines Ltd.17 0 1 SPHDFSanthera Pharmaceuticals Holding AG0 0 0 -
Is ONC or SPHDF More Risky?
BeOne Medicines Ltd. has a beta of 0.532, which suggesting that the stock is 46.826% less volatile than S&P 500. In comparison Santhera Pharmaceuticals Holding AG has a beta of -0.872, suggesting its less volatile than the S&P 500 by 187.184%.
-
Which is a Better Dividend Stock ONC or SPHDF?
BeOne Medicines Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Santhera Pharmaceuticals Holding AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BeOne Medicines Ltd. pays -- of its earnings as a dividend. Santhera Pharmaceuticals Holding AG pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ONC or SPHDF?
BeOne Medicines Ltd. quarterly revenues are $1.5B, which are larger than Santhera Pharmaceuticals Holding AG quarterly revenues of --. BeOne Medicines Ltd.'s net income of $66.8M is higher than Santhera Pharmaceuticals Holding AG's net income of --. Notably, BeOne Medicines Ltd.'s price-to-earnings ratio is 118.52x while Santhera Pharmaceuticals Holding AG's PE ratio is 1.45x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BeOne Medicines Ltd. is 6.33x versus 4.78x for Santhera Pharmaceuticals Holding AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ONCBeOne Medicines Ltd.6.33x 118.52x $1.5B $66.8M SPHDFSanthera Pharmaceuticals Holding AG4.78x 1.45x -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
49
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 37x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
42
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
93
NBTX alert for Mar 5
Nanobiotix SA [NBTX] is down 5.82% over the past day.
Sell
45
MRNA alert for Mar 5
Moderna, Inc. [MRNA] is down 3.79% over the past day.
Buy
77
SSRM alert for Mar 5
SSR Mining, Inc. [SSRM] is down 6.7% over the past day.
